Trebananib

Trebananib (also known as AMG-386) is a peptibody drug that was developed to inhibit angiogenesis, the process by which new blood vessels form. Angiogenesis is important for tumor growth and metastasis, and trebananib specifically targets the angiopoietin pathway, which is a key regulator of blood vessel stability and permeability. The drug binds to both angiopoietin‑1 and angiopoietin‑2 proteins, preventing them from stimulating the TIE2 receptor on the surface of endothelial cells. By blocking these signals, trebananib reduces the formation of new vasculature in tumors and can enhance the effectiveness of other anticancer therapies.

Clinical studies of trebananib have examined its use in ovarian, breast, colorectal, and glioblastoma cancers, among others. In early Phase I trials, the drug was generally well tolerated; observed adverse events included hypertension, proteinuria, and fatigue. A Phase II trial in patients with relapsed ovarian cancer demonstrated that trebananib added to chemotherapy improved progression‑free survival, although overall survival benefits were not definitively shown. Larger Phase III trials have been conducted, but results have been mixed, and the drug has not received widespread regulatory approval for oncology indications. Research continues to evaluate trebananib either as a single agent or in combination with cytotoxic or targeted therapies, with ongoing investigations into biomarkers that may predict which patients are most likely to benefit.